89bio reports fourth quarter and full year 2021 financial results and provides corporate update

– reported positive topline results from cohort 7 in the phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of nash –

ETNB Ratings Summary

ETNB Quant Ranking